![GHENT, BELGIUM (MARKET WIRE) Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies(R), a novel class of antibody-derived therapeutic proteins, announced today it has successfully generated Nanobodies(R) against several GPCR receptors. Furthermor...](/img/logo_new.gif){kind=logo}
PREVIEW
OF YOUR NEWS WIDGETScience - Chemicals latest news
OctoPlus N.V.: OctoPlus announces dates for AGM and for publication of 2007 annual report and 2008 half-year results
LEIDEN, NETHERLANDS (MARKET WIRE)
Marketwire.com Friday, October 10, 2008Ablynx: ABLYNX PROVIDES AN R&D UPDATE ANNOUNCING IT HAS SUCCESSFULLY GENERATED NANOBODIES(R) AGAINST GPCRs AND PRESENTS NEW PRECLINICAL DEVELOPMENT RANKL PROGRAMME
GHENT, BELGIUM (MARKET WIRE) Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies(R), a novel class of antibody-derived therapeutic proteins, announced today it has successfully generated Nanobodies(R) against several GPCR receptors. Furthermore, Ablynx will present during its R&D update in Ghent today, its new preclinical development programme ALX-0141, a Nanobody(R) against Receptor Activator for Nuclear Factor kappa B Ligand (RANKL), an important target for bone disorders such as osteoporosis. The Company also provided an update on the
Marketwire.com Friday, October 10, 2008
INSTALL YOUR WIDGET